ArticleACS central science2023
Nanopore Discrimination of Coagulation Biomarker Derivatives and Characterization of a Post-Translational Modification.
Article in ACS central science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Identification and Discrimination of Sulfated and Unsulfated Gut-Hormone Biomarkers in Human Serum by Nanopore.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Sub-Nanomolar Detection and Discrimination of Microcystin Congeners Using Aerolysin Nanopores.ACS nano · 2026Article
- Exopeptidase-assisted nanopore peptide sequence identification.Nature communications · 2026Article
- Nanopore Fingerprinting of Neurodegenerative Proteins and Phosphoproteins within a Minute.JACS Au · 2026Article
- Nanopore-based sensing for biomarker detection: from fundamental principles to translational diagnostics.Journal of nanobiotechnology · 2025Review
- Single-molecule nanopore sensing of prolineChemical science · 2025Article
- Nanopore sensing of protein and peptide conformation for point-of-care applications.Nature communications · 2025Review
- Direct Identification of O-Glycopeptides by Low-Temperature Assisted Nanopore Technique.Research (Washington, D.C.) · 2025Article
- Characterizing Prion-Like Protein Aggregation: Emerging Nanopore-Based Approaches.Small methods · 2024Review
- Real-Time Measurement of a Weak Interaction of a Transcription Factor Motif with a Protein Hub at Single-Molecule Precision.ACS nano · 2024Article
- Identification and Detection of a Peptide Biomarker and Its Enantiomer by Nanopore.ACS central science · 2024Article
- Bone Cement Implantation Syndrome: A Rare Disaster Following Cemented Hip Arthroplasties-Clinical Considerations Supported by Case Studies.Journal of personalized medicine · 2023Article
- Fibrinopeptide A Family Biomarker Identification at Single Molecule Level.ACS central science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the most important health challenges is the early and ongoing detection of disease for prevention, as well as personalized treatment management. Development of new sensitive analytical point-of-care tests are, therefore, necessary for direct biomarker detection from biofluids as critical tools to address the healthcare needs of an aging global population. Coagulation disorders associated with stroke, heart attack, or cancer are defined by an increased level of the fibrinopeptide A (FPA) biomarker, among others. This biomarker exists in more than one form: it can be post-translationally modified with a phosphate and also cleaved to form shorter peptides. Current assays are long and have difficulties in discriminating between these derivatives; hence, this is an underutilized biomarker for routine clinical practice. We use nanopore sensing to identify FPA, the phosphorylated FPA, and two derivatives. Each of these peptides is characterized by unique electrical signals for both dwell time and blockade level. We also show that the phosphorylated form of FPA can adopt two different conformations, each of which have different values for each electrical parameter. We were able to use these parameters to discriminate these peptides from a mix, thereby opening the way for the potential development of new point-of-care tests.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.